| Name | Title | Contact Details |
|---|---|---|
Wendy Vargas |
VP Global CO Project Leader Head, Rare Disease, Rare Blood Disorders, Oncology | Profile |
Sophie Forge |
VP - Global Head of Digital R&D Pipeline and Project analytics | Profile |
Andrey Malyy |
Global Head of Information Technology Solutions, Innovation, CX and Mobile | Profile |
Arnaud Robert |
Executive Vice President and Chief Digital Officer | Profile |
Michael Shanno |
Head of Digital and Information Technology | Profile |
Redmond and Greer Pharmacy Supply is a new and motivated corporation with many iconic brands in our portfolio. Our company began much like many independent pharmacies do, as a family business. Over a short time, the family business evolved into what is now one of the nation`s largest suppliers of niche market prescription medications and related products. Growing is at our heart and products are always changing use our expertise to make sure you`re on the forefront of these new products. Redmond and Greer Pharmacy Supply is a division of The Coney Consulting Group, LLC Our MISSION Our focus is providing value to our customers. We drive value to independent pharmacies by navigating the constantly changing business environment and keeping them in front of new products and profitable opportunities. Our VISION To be the preferred secondary wholesaler to the independent pharmacy market. Our VALUES Being pharmacist owned, we are highly focused on growing the business of the independent pharmacy. Our customers deserve the best, and to provide the best, we deliver all the tools a pharmacy needs to succeed – comprehensive product knowledge, access to pharmaceutical drugs at the best price, and a team that puts service and compliance above all else.
Pique Therapeutics is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.
Family Care Center provides counseling, medication management, and TMS. We specialize in mental health care for the entire family. Call today to learn more.
Adherium (ASX.ADR) is a global leader in digital health technologies which address sub-optimal medication use in chronic disease.